avacopan - Profile

What are the generic sources for avacopan and what is the scope of patent protection?

Avacopan is the generic ingredient in one branded drug marketed by Chemocentryx and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Avacopan has one hundred and thirty-one patent family members in thirty-nine countries.

Summary for avacopan

International Patents:	131
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for avacopan

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for avacopan

Constraining patent/regulatory exclusivity:

11,951,214

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for AVACOPAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAVNEOS	Capsules	avacopan	10 mg	214487	3	2025-11-13

US Patents and Regulatory Information for avacopan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	11,603,356		Y	Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	11,951,214		Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	8,906,938		Y	Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	8,445,515		Y	Y

EU/EMA Drug Approvals for avacopan

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vifor Fresenius Medical Care Renal Pharma France	Tavneos	avacopan	EMEA/H/C/005523Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).	Authorised	no	no	yes	2022-01-11

International Patents for avacopan

Country	Patent Number	Title	Estimated Expiration
Japan	6438086
Lithuania	C3508477
Morocco	54318
Norway	2022018

Supplementary Protection Certificates for avacopan

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2381778	122022000029	Germany		PRODUCT NAME: AVACOPAN; REGISTRATION NO/DATE: EU/1/21/1605 20220111
2381778	CA 2022 00022	Denmark		PRODUCT NAME: AVACOPAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/21/1605 20220119
2381778	202240009	Slovenia		PRODUCT NAME: AVACOPAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; NATIONAL AUTHORISATION NUMBER: EU/1/21/1605; DATE OF NATIONAL AUTHORISATION: 20220111; AUTHORITY FOR NATIONAL AUTHORISATION: EU
3508477	PA2022006,C3508477	Lithuania		PRODUCT NAME: AVAKOPANAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS ; REGISTRATION NO/DATE: EU/1/21/1605 20220111

Investment Scenario, Market Dynamics, and Financial Trajectory for Avacopan (CCX168)

Last updated: February 3, 2026

Summary

Avacopan (chemical name: CCX168) is a targeted therapy developed by ChemoCentryx for complement-mediated diseases, notably ANCA-associated vasculitis (AAV). Initially approved by regulatory agencies such as the U.S. FDA in October 2021, avacopan offers an alternative to corticosteroid-based regimens, promising better safety profiles and long-term health outcomes. The drug’s market potential hinges on evolving disease prevalence, competitive landscape, and regulatory decisions. Investment prospects require understanding clinical efficacy, regulatory pathways, competitive positioning, and commercialization strategies.

---

What Is the Current Market Status and Regulatory Approval of Avacopan?

Attribute	Details
Regulatory Approval	FDA (October 2021), EMA (March 2022) for AAV treatment, marketed as Tavneos® (United States)
Indications	Adult patients with ANCA-associated vasculitis, with or without renal involvement
Approval Reason	Demonstrated efficacy in inducing remission with fewer corticosteroid-related adverse effects (ChemoCentryx, 2021)
Initial Market Launch	U.S. market entry in late 2021; subsequent expansion to Europe and other regions

Implication for Investment:
Regulatory approval positions avacopan as a potentially standard-of-care option within its indication. Early adoption, especially in regions with established vasculitis treatment protocols, could accelerate revenue generation.

---

Market Dynamics

1. Disease Prevalence and Demographics

Parameter	Data	Source
ANCA-Associated Vasculitis (AAV) Prevalence	Approx. 10-20 cases per million annually	[1], (Falk et al., 2020)
Population at Risk	Mostly adults aged 50-70 years	Clinical data
Global Prevalence Estimate	0.78 - 1.58 million cases worldwide	Based on epidemiologic models

2. Competitive Landscape

Competitors	Key Products / Strategies	Market Position
Rituximab (Roche, FDA-approved for AAV)	B-cell depletion agent, standard in AAV treatment	Market leader; high penetration in severe cases
Cyclophosphamide	Chemotherapy agent, nonspecific immunosuppressant	Traditional, less favored due to toxicity
Complement pathway inhibitors in Phase II/III	Competing molecules targeting C5a, C3; limited approvals	Emerging competition but limited market penetration
Steroids (Corticosteroids)	Mainstay but with significant long-term adverse effects	Adjunctive, with a shift towards steroid-sparing agents like avacopan

3. Market Penetration Drivers

• Clinical Efficacy: Avacopan reduces corticosteroid use, improving safety.
• Regulatory Acceptance: Acceptance by global agencies increases access.
• Physician Adoption: Education and clinical guidelines influence prescribing patterns.
• Pricing & Rebate Policies: Payer negotiations impact adoption rate.
• Access Programs: Orphan and rare disease designations can improve reimbursement.

---

Financial Trajectory Analysis

1. Revenue Drivers

Factor	Considerations	Impact
Pricing	Estimated annual wholesale acquisition cost (WAC) per patient: \$30,000–\$50,000	High margins, depending on reimbursement
Patient Population	Approx. 2,000-4,000 patients in the U.S. (initial target); expanding globally	Size influences maximum revenue potential
Reimbursement Trends	Payer coverage expected to favor corticosteroid-sparing agents	Accelerates sales volume
Market Penetration Rate	10%-50% within 5 years post-launch	Conservative vs. aggressive uptake scenarios
Additional Indications	Potential for other complement-mediated diseases like hidradenitis suppurativa	Future revenue streams

2. Cost Structure

Category	Estimate/Observation	Relevance
R&D	Already incurred; ongoing development costs for ancillary indications	Cap ex/Op ex impact
Manufacturing	Scale-up costs (~\$150–\$300 per vial at scale)	Margin optimization
Marketing & Sales	Significant expenditure in educating physicians and payers	Critical for adoption
Regulatory & Post-approval	Label expansions and pharmacovigilance	Potential for additional investments

3. Financial Forecasts

Scenario	Year 1 (2023-24)	Year 3 (2025-26)	Year 5 (2027-28)
Conservative	\$50M in sales; 10% market share	\$150M; 20% market share	\$300M; expanded indications
Optimistic	\$150M; 30% market share	\$400M; increased adoption	\$800M+; broader indications

(Assumptions: Stable pricing, moderate market acceptance, no significant competitor disruption)

---

Comparative Analysis: Avacopan vs. Market Competitors

Attribute	Avacopan	Rituximab	Cyclophosphamide	Emerging Therapies
Regulatory Status	Approved in US & EU	Approved	Approved	Clinical trials phase
Mechanism of Action	C5a receptor inhibition	B-cell depletion	Cytotoxic immunosuppressive	Varied (e.g., C5a, C3 inhibitors)
Safety Profile	Favorable; steroid-sparing	Good but with infusion reactions	Significant toxicity	Varies, under assessment
Cost	\$30k–\$50k/year	Similar or higher	Lower but with toxicity costs	TBD

---

Policy and Reimbursement Considerations

Policy Element	Implication for Avacopan	Additional Notes
Orphan Drug Designation	Facilitates exclusivity, tax credits	ChemoCentryx holds such designations in multiple markets
Pricing & Reimbursement	Payer acceptance dependent on cost-effectiveness	Health technology assessments (HTA) influence uptake
Companion Diagnostics	Not required currently	Might evolve with personalized approaches
International Approvals	Pathways vary; China, Japan, Canada	Potential for substantial revenue if achieved

---

Key Investment Rationale

• Early-mover advantage in the niche complement-mediated vasculitis market.
• Strong clinical data supporting efficacy and safety position avacopan favorably.
• Potential expansion into other indications representing multibillion-dollar markets.
• Regulatory protections through orphan drug status and patents.
• Pipeline development may further de-risk or augment revenue streams.

---

Potential Risks

Risk Category	Details	Mitigation Strategies
Regulatory	Delays or rejection in key markets	Engage early with regulators, provide robust data
Market Acceptance	Slow physician adoption	Comprehensive education campaigns
Pricing & Reimbursement	Resistance from payers	Demonstrate cost-effectiveness
Competition	Emerging therapies with superior profiles	Accelerate pipeline, develop secondary indications
Manufacturing/Supply	Scalability issues	Parallel manufacturing agreements

---

Conclusion: Investment Outlook Summary

Aspect	Assessment
Market Potential	High in niche rare diseases; scalability to broader complement-mediated diseases
Regulatory Status	Approved with ongoing expansion opportunities
Competitive Edge	Differentiated mechanism with improved safety profile
Financial Trajectory	Optimistic scenarios project multi-hundred-million-dollar revenues within 5 years
Risks	Regulatory, market, and competitive risks necessitate strategic planning

Overall, avacopan presents a compelling investment opportunity within the niche autoimmune and vasculitis markets, buoyed by its innovative mechanism, favorable safety profile, and ongoing pipeline expansion.

---

Key Takeaways

• Market Size & Growth: Estimated 10,000-20,000 eligible patients globally, with potential expansion into other complement-mediated disorders.
• Revenue Forecast: Optimistic projections suggest \$300M–\$800M annually by 2027, assuming swift adoption.
• Competitive Differentiation: Unique mechanism with demonstrable safety benefits positions avacopan favorably against traditional therapies.
• Regulatory & Policy Environment: Supportive orphan drug designations accelerate market access and exclusivity.
• Risks & Opportunities: Critical to monitor regulatory developments, payer acceptance, and pipeline progress for risk mitigation.

---

References

1. Falk, R., et al. (2020). “Epidemiology of ANCA-Associated Vasculitis: International Differences and Disease Burden.” Rheumatology.
2. ChemoCentryx. (2021). “FDA Approves Tavneos (avacopan) for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.” Press Release.
3. European Medicines Agency (EMA). (2022). “Approval of Tavneos for AAV.”
4. ClinicalTrials.gov. (Various). “Avacopan Clinical Trial Data.”
5. MarketWatch and industry reports for pricing and market estimates.

---

Note: Data and projections are based on publicly available information and industry estimates as of 2023. Actual results may vary.